Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Zentalis Pharmaceuticals has received a consensus recommendation of "Moderate Buy" from six research firms, with an average twelve-month target price of $8.37.
• Significant institutional investment increases were noted, such as Millennium Management LLC boosting its stake by 220.6% in the first quarter.
• The company's stock opened at $1.41 and has a market cap of $101.45 million, with analysts predicting earnings per share of -2.42 for the current fiscal year.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six research firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $8.3667.

ZNTL has been the topic of a number of research reports. Wedbush restated a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Millennium Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock worth $4,881,000 after acquiring an additional 2,111,951 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 150.6% in the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company's stock worth $4,244,000 after acquiring an additional 1,606,802 shares in the last quarter. Integral Health Asset Management LLC bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth about $3,182,000. Almitas Capital LLC increased its holdings in shares of Zentalis Pharmaceuticals by 69.3% in the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock worth $4,929,000 after acquiring an additional 665,968 shares in the last quarter. Finally, Peapod Lane Capital LLC bought a new stake in shares of Zentalis Pharmaceuticals in the first quarter worth about $888,000.

Zentalis Pharmaceuticals Stock Performance

ZNTL opened at $1.41 on Wednesday. The business has a 50 day moving average price of $1.36 and a 200 day moving average price of $1.57. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $5.44. The firm has a market cap of $101.45 million, a P/E ratio of -0.45 and a beta of 1.71.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting the consensus estimate of ($0.67). As a group, analysts anticipate that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.